The efficacy of Cisatracurium Besylate Injection to provide skeletal muscle relaxation to facilitate tracheal intubation during surgery was established in six studies in adult patients. In all these studies patients had general anesthesia and mechanical ventilation.
In Study 1, the clinically effective duration of action for 0.15 and 0.2 mg/kg Cisatracurium Besylate Injection using propofol anesthesia was 55 minutes (range: 44 to 74 minutes) and 61 minutes (range: 41 to 81 minutes), respectively.
In Studies 2 and 3, Cisatracurium Besylate Injection doses of 0.25 and 0.4 mg/kg were evaluated in 30 patients under opioid/nitrous oxide/oxygen anesthesia and provided 78 (66–86) and 91 (59–107) minutes of clinical relaxation, respectively.
In Study 4, two minutes after fentanyl and midazolam were administered, patients received thiopental anesthesia. Intubating conditions were assessed at 120 seconds following administration of 0.15 mg/kg or 0.2 mg/kg of Cisatracurium Besylate Injection in 51 patients (see Table 11).
| Cisatracurium Besylate 0.15 mg/kg (n = 26) | Cisatracurium Besylate 0.20 mg/kg (n = 25) | |
|---|---|---|
| *Excellent: Easy passage of tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. | ||
Excellent and Good | 88% | 96% |
95% CI | 76,100 | 88,100 |
Excellent | 31% | 60% |
Good | 58% | 36% |
Excellent intubating conditions were more frequently achieved with the 0.2 mg/kg dose (60%) than the 0.15 mg/kg dose (31%) when intubation was attempted 120 seconds following cisatracurium.
Study 5 evaluated intubating conditions after 3 and 4 × ED95 (0.15 mg/kg and 0.20 mg/kg) following induction with fentanyl and midazolam and either thiopental or propofol anesthesia. This study compared intubation conditions produced by these doses of cisatracurium after 90 seconds. Table 12 displays these results.
| Intubating Conditions | Cisatracurium Besylate 0.15 mg/kg with Propofol (n = 31) | Cisatracurium Besylate 0.15 mg/kg with Thiopental (n = 31) | Cisatracurium Besylate 0.20 mg/kg with Propofol (n = 30) | Cisatracurium Besylate 0.20 mg/kg with Thiopental (n = 28) |
|---|---|---|---|---|
| * Excellent: Easy passage of tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. | ||||
Excellent and Good | 94% | 90% | 93% | 96% |
95% CI | 85,100 | 80,100 | 84,100 | 90,100 |
Excellent | 58% | 55% | 70% | 57% |
Good | 35% | 35% | 20% | 39% |
Excellent intubating conditions were more frequently observed with the 0.2 mg/kg dose when intubation was attempted 90 seconds following cisatracurium.
The efficacy of Cisatracurium Besylate Injection to provide skeletal muscle relaxation to facilitate tracheal intubation was established in studies in pediatric patients aged 1 month to 12 years old. In these studies, patients had general anesthesia and mechanical ventilation.
In Study 6, a Cisatracurium Besylate Injection dose of 0.1 mg/kg was evaluated in 16 pediatric patients (ages 2 years to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of 2.8 minutes (range: 1.8 to 6.7 minutes) with a clinically effective block for 28 minutes (range: 21 to 38 minutes).
In Study 7, a Cisatracurium Besylate Injection dose of 0.15 mg/kg was evaluated in 50 pediatric patients (ages 1 month to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of about 3 minutes (range: 1.5 to 8 minutes) with a clinically effective block for 36 minutes (range: 29 to 46 minutes) in 24 patients ages 2 to 12 years. In 27 infants (1 to 23 months), maximum neuromuscular block was achieved in about 2 minutes (range: 1.3 to 4.3 minutes) with a clinically effective block for about 43 minutes (range: 34 to 58 minutes) with this dose.
Study 7 also evaluated intubating conditions in 180 pediatric patients (ages 1 month to 12 years) after administration of Cisatracurium Besylate Injection doses of 0.15 mg/kg following induction with either halothane (with halothane/nitrous oxide/oxygen maintenance) or thiopentone and fentanyl (with thiopentone/fentanyl nitrous oxide/oxygen maintenance). Table 13 displays the intubating conditions by type of anesthesia, and pediatric age group. Excellent or good intubating conditions were produced 120 seconds following 0.15 mg/kg of cisatracurium besylate in 88/90 (98%) of patients induced with halothane and in 85/90 (94%) of patients induced with thiopentone and fentanyl. There were no patients for whom intubation was not possible, but there were 7/120 patients aged 1 year to 12 years old for whom intubating conditions were described as poor.
| Cisatracurium Besylate 0.15 mg/kg 1–11 mo. | Cisatracurium Besylate 0.15 mg/kg 1–4 years | Cisatracurium Besylate 0.15 mg/kg 5–12 years | ||||
|---|---|---|---|---|---|---|
| Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | |
| * Excellent: Easy passage of the tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. Poor: Passage of tube with moderate coughing and/or bucking. Vocal cords moderately adducted. Response of patient requires adjustment of ventilation pressure and/or rate. | ||||||
Excellent and Good | 100% | 100% | 97% | 87% | 97% | 97% |
Excellent | 100% | 83% | 90% | 63% | 73% | 70% |
Good | 0% | 17% | 7% | 23% | 23% | 27% |
Poor | 0% | 0% | 3% | 13% | 3% | 3% |
Long-term infusion (up to 6 days) of cisatracurium besylate during mechanical ventilation in the ICU was evaluated in two studies.
Study 8 was a randomized, double-blind study using presence of a single twitch during train-of-four (TOF) monitoring to regulate dosage. Patients treated with cisatracurium besylate (n = 19) recovered neuromuscular function (T4:T1 ratio ≥ 70%) following termination of infusion in approximately 55 minutes (range: 20 to 270).
In Study 9, cisatracurium besylate patients recovered neuromuscular function in approximately 50 minutes (range: 20 to 175; n = 34).
The efficacy of Cisatracurium Besylate Injection to provide skeletal muscle relaxation to facilitate tracheal intubation during surgery was established in six studies in adult patients. In all these studies patients had general anesthesia and mechanical ventilation.
In Study 1, the clinically effective duration of action for 0.15 and 0.2 mg/kg Cisatracurium Besylate Injection using propofol anesthesia was 55 minutes (range: 44 to 74 minutes) and 61 minutes (range: 41 to 81 minutes), respectively.
In Studies 2 and 3, Cisatracurium Besylate Injection doses of 0.25 and 0.4 mg/kg were evaluated in 30 patients under opioid/nitrous oxide/oxygen anesthesia and provided 78 (66–86) and 91 (59–107) minutes of clinical relaxation, respectively.
In Study 4, two minutes after fentanyl and midazolam were administered, patients received thiopental anesthesia. Intubating conditions were assessed at 120 seconds following administration of 0.15 mg/kg or 0.2 mg/kg of Cisatracurium Besylate Injection in 51 patients (see Table 11).
| Cisatracurium Besylate 0.15 mg/kg (n = 26) | Cisatracurium Besylate 0.20 mg/kg (n = 25) | |
|---|---|---|
| *Excellent: Easy passage of tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. | ||
Excellent and Good | 88% | 96% |
95% CI | 76,100 | 88,100 |
Excellent | 31% | 60% |
Good | 58% | 36% |
Excellent intubating conditions were more frequently achieved with the 0.2 mg/kg dose (60%) than the 0.15 mg/kg dose (31%) when intubation was attempted 120 seconds following cisatracurium.
Study 5 evaluated intubating conditions after 3 and 4 × ED95 (0.15 mg/kg and 0.20 mg/kg) following induction with fentanyl and midazolam and either thiopental or propofol anesthesia. This study compared intubation conditions produced by these doses of cisatracurium after 90 seconds. Table 12 displays these results.
| Intubating Conditions | Cisatracurium Besylate 0.15 mg/kg with Propofol (n = 31) | Cisatracurium Besylate 0.15 mg/kg with Thiopental (n = 31) | Cisatracurium Besylate 0.20 mg/kg with Propofol (n = 30) | Cisatracurium Besylate 0.20 mg/kg with Thiopental (n = 28) |
|---|---|---|---|---|
| * Excellent: Easy passage of tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. | ||||
Excellent and Good | 94% | 90% | 93% | 96% |
95% CI | 85,100 | 80,100 | 84,100 | 90,100 |
Excellent | 58% | 55% | 70% | 57% |
Good | 35% | 35% | 20% | 39% |
Excellent intubating conditions were more frequently observed with the 0.2 mg/kg dose when intubation was attempted 90 seconds following cisatracurium.
The efficacy of Cisatracurium Besylate Injection to provide skeletal muscle relaxation to facilitate tracheal intubation was established in studies in pediatric patients aged 1 month to 12 years old. In these studies, patients had general anesthesia and mechanical ventilation.
In Study 6, a Cisatracurium Besylate Injection dose of 0.1 mg/kg was evaluated in 16 pediatric patients (ages 2 years to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of 2.8 minutes (range: 1.8 to 6.7 minutes) with a clinically effective block for 28 minutes (range: 21 to 38 minutes).
In Study 7, a Cisatracurium Besylate Injection dose of 0.15 mg/kg was evaluated in 50 pediatric patients (ages 1 month to 12 years) during opioid anesthesia. When administered during stable opioid/nitrous oxide/oxygen anesthesia, maximum neuromuscular blockade was achieved in an average of about 3 minutes (range: 1.5 to 8 minutes) with a clinically effective block for 36 minutes (range: 29 to 46 minutes) in 24 patients ages 2 to 12 years. In 27 infants (1 to 23 months), maximum neuromuscular block was achieved in about 2 minutes (range: 1.3 to 4.3 minutes) with a clinically effective block for about 43 minutes (range: 34 to 58 minutes) with this dose.
Study 7 also evaluated intubating conditions in 180 pediatric patients (ages 1 month to 12 years) after administration of Cisatracurium Besylate Injection doses of 0.15 mg/kg following induction with either halothane (with halothane/nitrous oxide/oxygen maintenance) or thiopentone and fentanyl (with thiopentone/fentanyl nitrous oxide/oxygen maintenance). Table 13 displays the intubating conditions by type of anesthesia, and pediatric age group. Excellent or good intubating conditions were produced 120 seconds following 0.15 mg/kg of cisatracurium besylate in 88/90 (98%) of patients induced with halothane and in 85/90 (94%) of patients induced with thiopentone and fentanyl. There were no patients for whom intubation was not possible, but there were 7/120 patients aged 1 year to 12 years old for whom intubating conditions were described as poor.
| Cisatracurium Besylate 0.15 mg/kg 1–11 mo. | Cisatracurium Besylate 0.15 mg/kg 1–4 years | Cisatracurium Besylate 0.15 mg/kg 5–12 years | ||||
|---|---|---|---|---|---|---|
| Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | Halothane Anesthesia (n=30) | Thiopentone/Fentanyl Anesthesia (n=30) | |
| * Excellent: Easy passage of the tube without coughing. Vocal cords relaxed and abducted. Good: Passage of tube with slight coughing and/or bucking. Vocal cords relaxed and abducted. Poor: Passage of tube with moderate coughing and/or bucking. Vocal cords moderately adducted. Response of patient requires adjustment of ventilation pressure and/or rate. | ||||||
Excellent and Good | 100% | 100% | 97% | 87% | 97% | 97% |
Excellent | 100% | 83% | 90% | 63% | 73% | 70% |
Good | 0% | 17% | 7% | 23% | 23% | 27% |
Poor | 0% | 0% | 3% | 13% | 3% | 3% |
Long-term infusion (up to 6 days) of cisatracurium besylate during mechanical ventilation in the ICU was evaluated in two studies.
Study 8 was a randomized, double-blind study using presence of a single twitch during train-of-four (TOF) monitoring to regulate dosage. Patients treated with cisatracurium besylate (n = 19) recovered neuromuscular function (T4:T1 ratio ≥ 70%) following termination of infusion in approximately 55 minutes (range: 20 to 270).
In Study 9, cisatracurium besylate patients recovered neuromuscular function in approximately 50 minutes (range: 20 to 175; n = 34).
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.